Topics

SGLT2 Inhibitors in T2D Tied to New Risk Reduction Benefit

12:45 EST 13 Jan 2020 | MedPageToday

]]>(MedPage Today) -- Individuals with type 2 diabetes on sodium-glucose cotransporter-2 (SGLT2) inhibitors may see a reduced gout risk, according to a population-based cohort study. Compared to patients on a newly initiated glucagon-like peptide...

Original Article: SGLT2 Inhibitors in T2D Tied to New Risk Reduction Benefit

NEXT ARTICLE

More From BioPortfolio on "SGLT2 Inhibitors in T2D Tied to New Risk Reduction Benefit"

Quick Search

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Gout
According to the National Arthritis Data Workgroup, an estimated 6 million people in the United States report having experienced gout at some point in their lives. In fact, gout is the most common form of inflammatory arthritis in men over the age of 40....